Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Department of Colorectal Surgery, Western General Hospital, Edinburgh, UK.
BJS Open. 2024 Sep 3;8(5). doi: 10.1093/bjsopen/zrae119.
This study aimed to describe the faecal immunochemical test non-return rate of those referred with high-risk symptoms of colorectal cancer from primary care, and the clinical outcomes of the 'non-returners'.
From January 2019 to July 2021, patients referred to secondary care with symptoms suspicious of colorectal cancer and a referral priority of urgent or urgent suspicion of cancer were sent a faecal immunochemical test. All patients were investigated regardless of faecal immunochemical test return or result. Demographics and clinical outcomes such as colorectal cancer prevalence were compared between those who returned a faecal immunochemical test and non-returners.
Of 7345 patients included in the study, 874 (11.9%) did not return a faecal immunochemical test. Non-returner characteristics included male sex (P = 0.040), younger age (median age 57 versus 65 years, P < 0.001), per rectal bleeding (P < 0.001) and lower socioeconomic status (median Scottish Index of Multiple Deprivation, 6 versus 7, P < 0.001) compared with those who returned a faecal immunochemical test. Of 6294 patients undergoing colorectal investigation, there was a greater prevalence of colorectal cancer (5.4% versus 3.6% P = 0.032) and significant bowel pathology than in the non-returners (15.3% versus 9.8%, P < 0.001). With a median follow-up of 25 months, the colorectal cancer prevalence for the entire 7345 cohort was equal between those who returned and did not return a faecal immunochemical test (3.2% versus 3.8%, P = 0.108). Of note, the non-returners diagnosed with colorectal cancer were younger (median age 64 versus 73 years, P < 0.001) and from a lower socioeconomic area (median Scottish Index of Multiple Deprivation 4 versus 7, P = 0.015) than faecal immunochemical test returners.
Patients referred to secondary care, with symptoms suspicious of colorectal cancer, that did not return a faecal immunochemical test had a similar colorectal cancer prevalence to those that returned the test.
本研究旨在描述从初级保健转介的高危结直肠癌症状患者的粪便免疫化学检测未回复率,以及“未回复者”的临床结局。
从 2019 年 1 月至 2021 年 7 月,将有疑似结直肠癌症状且转诊优先级为紧急或疑似癌症的患者转诊至二级保健机构,并向其发送粪便免疫化学检测。无论粪便免疫化学检测是否返回或结果如何,所有患者均接受调查。比较返回粪便免疫化学检测和未返回的患者的人口统计学和临床结局,如结直肠癌患病率。
在纳入研究的 7345 例患者中,874 例(11.9%)未返回粪便免疫化学检测。未回复者的特征包括男性(P = 0.040)、年龄较小(中位年龄 57 岁与 65 岁,P < 0.001)、直肠出血(P < 0.001)和较低的社会经济地位(中位苏格兰多重剥夺指数 6 与 7,P < 0.001)与返回粪便免疫化学检测者相比。在 6294 例接受结直肠检查的患者中,结直肠癌的患病率(5.4%与 3.6%,P = 0.032)和显著的肠道病理情况均高于未回复者(15.3%与 9.8%,P < 0.001)。中位随访 25 个月后,在整个 7345 例队列中,返回和未返回粪便免疫化学检测的患者结直肠癌患病率相等(3.2%与 3.8%,P = 0.108)。值得注意的是,诊断为结直肠癌的未回复者年龄较小(中位年龄 64 岁与 73 岁,P < 0.001),且来自社会经济水平较低的地区(中位苏格兰多重剥夺指数 4 与 7,P = 0.015)。
转诊至二级保健机构、有疑似结直肠癌症状且未回复粪便免疫化学检测的患者的结直肠癌患病率与回复检测的患者相似。